Combinatorial therapy utilising benazepril and moxibustion significantly inhibits cardiac ERS biomarkers, including phosphorylated PERK (p‐PERK) and phosphorylated eukaryotic initiation factor 2α (p‐eIF2α), thereby ameliorating chronic heart failure progression in murine models. Here, EIF2AK3 is linked to congestive heart failure.